ProfileGDS5678 / 1455978_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 87% 83% 84% 86% 88% 87% 89% 85% 78% 84% 84% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4524786
GSM967853U87-EV human glioblastoma xenograft - Control 26.2588484
GSM967854U87-EV human glioblastoma xenograft - Control 36.6434287
GSM967855U87-EV human glioblastoma xenograft - Control 46.1743483
GSM967856U87-EV human glioblastoma xenograft - Control 56.2669284
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.307186
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6556288
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7205887
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9590889
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4038285
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3991478
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2179484
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2831184
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3713985